
Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Brooke is an associate editor for The American Journal of Managed Care® (AJMC®). She joined AJMC in 2023, where she produces content covering multiple disease states.
She has a BA in journalism from Seton Hall University. You can connect with Brooke on LinkedIn.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

Crescent Moore, PharmD, PhD, explained how health plans can evaluate menopause therapies, audit coverage, and measure outcomes beyond spending.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.

In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections could shape legislation.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.

In an interview at AMCP Nexus 2026, Carmen Witsken, PharmD, of ACHP, outlined a proposed national risk pool for the costliest cell and gene therapies.

In part 2, Susan M. Wescott, RPh, MBA, discusses how payers navigate evidence gaps, prior authorization, and access to rare disease therapies.

In part 2 of her AMCP Nexus 2026 interview, Jennifer S. Graff, PharmD, discusses improving patient experience data (PED) standardization and credibility.

At AMCP Nexus 2026, experts discussed how drug pricing policy, AI, and high-cost cell and gene therapies may shape managed care in 2027.

In part 2, Leanna Baker, PharmD, MS, of Cencora discusses the ongoing costs, governance, and oversight needed for responsible AI adoption.

Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.

At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.

Crescent Moore, PharmD, PhD, discusses provider, coverage, stigma, and education barriers to menopause therapy access.

The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

Adam Colborn, JD, discusses 340B reform, PBM policy, site-neutral payment, and other federal health policy issues to watch in 2027.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower treatment costs.

Jennifer S. Graff, PharmD, said payers need clearer standards to assess the reliability and credibility of patient experience data.

Managed care organizations should start AI adoption with simple tools that build governance for future growth, Leanna Baker, PharmD, MS, said.

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

Mark Fendrick, MD, discusses survey findings on deprescribing GLP-1 RAs after weight loss as the CMS GLP-1 Bridge Model nears expiration.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

Published: January 27th 2026 | Updated: February 3rd 2026

Published: October 21st 2024 | Updated: October 24th 2024